ADAM33 and asthma: In our study, we found that T2, Q1 and F + 1 polymorphisms of ADAM33 were significantly associated with increased the asthma risk in Chinese asthma patients, indicating that ADAM33 might be a promising biomarker and therapeutic option for asthma.